Compare EMN & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EMN | NUVL |
|---|---|---|
| Founded | 1920 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0B | 8.1B |
| IPO Year | 1996 | 2021 |
| Metric | EMN | NUVL |
|---|---|---|
| Price | $67.59 | $100.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 15 |
| Target Price | $78.57 | ★ $135.33 |
| AVG Volume (30 Days) | ★ 1.3M | 427.0K |
| Earning Date | 04-30-2026 | 05-27-2026 |
| Dividend Yield | ★ 4.85% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 4.10 | N/A |
| Revenue | ★ $8,752,000,000.00 | N/A |
| Revenue This Year | $1.75 | N/A |
| Revenue Next Year | $3.32 | $1,064.25 |
| P/E Ratio | $16.94 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $56.11 | $55.54 |
| 52 Week High | $94.11 | $113.02 |
| Indicator | EMN | NUVL |
|---|---|---|
| Relative Strength Index (RSI) | 30.66 | 44.59 |
| Support Level | $66.44 | $98.37 |
| Resistance Level | $70.51 | $107.13 |
| Average True Range (ATR) | 2.73 | 3.75 |
| MACD | -1.32 | -0.14 |
| Stochastic Oscillator | 4.82 | 24.54 |
Established in 1920 to produce chemicals for Eastman Kodak, Eastman Chemical has grown into a global specialty chemical company with manufacturing sites around the world. The company generates the majority of its sales outside of the United States, with a strong presence in Asian markets. During the past several years, Eastman has sold noncore businesses, choosing to focus on higher-margin specialty product offerings.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.